Dermal trypanosomes in suspected and confirmed cases of *gambiense* Human 1

African Trypanosomiasis. 2

Mariame Camara¹ (M.D.), Alseny M'mah Soumah^{1,2} (M.D.), Hamidou Ilbouldo^{1,3,4} (Ph.D.), 3

Christelle Travaillé⁵ (Ph.D.), Caroline Clucas⁶ (Ph.D.), Anneli Cooper⁶ (Ph.D.), Nono-Raymond 4

Kuispond Swar^{6,7} (M.D.), Oumou Camara¹, Ibrahim Sadissou⁴ (PhD), Estefania Calvo Alvarez⁵ 5

6 (Ph.D.), Aline Crouzols⁵, Jean-Mathieu Bart⁴ (PhD), Vincent Jamonneau⁴ (Ph.D.), Mamadou

Camara¹ (Ph.D.), Annette MacLeod⁶* (Ph.D.), Bruno Bucheton^{1,4}* (Ph.D.) and Brice 7

Rotureau⁵*# (Ph.D.) 8

9

10	¹ Programme	National de Lutte d	ontre la Trypano	somiase Humaine	Africaine, N	/linistère de la
-	-0		/		/	

11 Santé, Conakry, Guinea

² Service de Dermatologie, Hôpital de Donka, Conakry, Guinea 12

³ Institut de Recherche en Sciences de la Santé (IRSS) - Unité de Recherche Clinique de Nanoro 13

14 (URCN), Nanoro, Burkina-Faso

⁴ Institut de Recherche pour le Développement, Unité Mixte de Recherche IRD-CIRAD 177 15

16 InterTryp, Campus International de Baillarguet, Montpellier, France

17 ⁵ Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201 &

Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France 18

⁶ Wellcome Centre for Molecular Parasitology, College of Medical, Veterinary and Life 19

20 Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland,

United Kingdom 21

⁷ Department of Parasitology, National Institute of Biomedical Research (INRB), Kinshasa, 22

23 Democratic Republic of the Congo

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 * Joint last authors

- 26 [#] Corresponding author: Brice Rotureau, PhD, Trypanosome Transmission Group,
- 27 Trypanosome Cell Biology Unit, INSERM U1201 & Department of Parasites and Insect Vectors,
- 28 Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France, rotureau@pasteur.fr, Tel +33
- 29 (0)1 40 61 38 33

30

31 Short title

32 Dermal trypanosomes in gHAT cases and suspects

33

34 Keywords

35 Skin, reservoir, carriers, Human African Trypanosomiasis, *Trypanosoma brucei gambiense*.

36 Abstract (244 words)

37 Background

The diagnosis of Human African Trypanosomiasis (HAT) typically involves two steps: a serological screen, followed by the detection of living trypanosome parasites in the blood or lymph node aspirate. Live parasites can, however, remain undetected in some seropositive individuals, who we hypothesize are infected with *Trypanosoma brucei gambiense* parasites in their extravascular dermis.

43 Methods and findings

To test this hypothesis, we conducted a prospective observational cohort study in the 44 gambiense HAT (gHAT) focus of Forecariah, in the Republic of Guinea. 5,417 subjects in this 45 46 disease foci underwent serological screening for gHAT. Of these individuals, 66 were enrolled 47 into our study, of whom 40 were seronegative, 8 were seropositive but unconfirmed, and 18 confirmed gHAT cases. Enrolled individuals underwent a dermatological examination, and had 48 49 blood samples and skin biopsies taken and examined for trypanosomes by molecular and 50 immuno-histological methods. In confirmed cases, dermatological symptoms were 51 significantly more frequent, relative to seronegative controls. T. b. gambiense parasites were 52 present in the blood of all confirmed cases but not in unconfirmed seropositive individuals. 53 However, trypanosomes were detected in the dermis of all unconfirmed seropositive 54 individuals and confirmed cases. After 6 and 20 months of treatment, dermal trypanosome numbers in skin biopsies of confirmed cases progressively reduced. 55

56 <u>Conclusions</u>

Our results thus highlight the skin as a potential reservoir for trypanosomes, with implications
for our understanding of this disease's epidemiology in the context of its planned elimination
and highlighting the skin as a novel target for gHAT diagnostics.

60 Introduction

61 *Trypanosoma brucei gambiense* is a protist parasite that is transmitted by the bite of the tsetse fly and causes Human African Trypanosomiasis (gHAT, also known as sleeping sickness), in 62 Western and Central Africa [1]. The epidemiological importance of animal reservoirs of 63 trypanosomes is not well-characterized [2] and these parasites are considered to mostly 64 65 circulate in human populations in discrete endemic foci, with approximately 13 million people at risk [3]. The number of new cases has never been so low in the known epidemiological 66 67 history of the disease, with only ~1,500 new cases reported in 2017 [4], and the World Health Organization (WHO) has targeted gHAT elimination by 2030 [3]. This objective has been 68 encouraged by the success of active surveillance efforts that relies on a two-step diagnosis: 69 70 an initial serological screen, followed by microscope observation of blood, lymph or 71 cerebrospinal fluid (CSF) to detect extracellular trypanosomes and to confirm the serological 72 diagnosis. However, some seropositive individuals remain without a confirmed parasitological 73 diagnosis for years. Such, individuals have been recently described as being latent cases, 74 raising the question as to whether reservoirs of live parasites persist in these individuals [5]. 75 The role of skin in the transmission of arthropod-borne protozoan parasites has been 76 overlooked for several decades [6]. T. brucei s. I. parasites are found in the extravascular 77 compartment of various tissues of their mammalian hosts, including the skin, albeit mostly under experimental conditions in animal models rather than during the natural progression 78 79 of the disease [7]. Recently, the extravascular tropism of African trypanosomes was re-visited

in light of the new molecular and imaging technologies that are now available in animal
models [8-10]. Such studies have revealed that substantial quantities of trypanosomes persist
within the extravascular dermis following experimental infection in mice with *T. b. gambiense*or *T. b. brucei*. These parasites can be transmitted to the tsetse vector, even in the absence of

84 detectable parasites in the host's blood [9]. This study also reported a retrospective screening of archived skin biopsies from a gHAT endemic region, which revealed the presence of some 85 86 extravascular skin-dwelling trypanosomes [9]. However, the species of these parasites was 87 not identified and no clinical records were available for the screened samples. 88 These observations raise the question as to whether *T. b. gambiense* might be found in the 89 skin of confirmed gHAT cases, as well as in unconfirmed seropositive individuals, in regions of active disease transmission. To address this question, we performed a prospective 90 91 observational study in the Forecariah district in the Republic of Guinea, which is one of the 92 most active gHAT foci in Western Africa.

93 Methods

94 Ethical approval

All investigations were conducted in accordance with the Declaration of Helsinki and fulfil the
STROBE criteria. Approval for this study was obtained from the consultative committee for
deontology and ethics at the Institut de Recherche pour le Développement and from the
National Ethical Committee of the Republic of Guinea (Study Diag-Cut-THA 032/CNERS/17 and
amendment 038/CNERS/19).

100 Study enrolment, screening, and case definitions

101 All subjects enrolled in this study came from 43 villages in the active gHAT focus of the 102 Forecariah District, which is located in a coastal mangrove area of the Republic of Guinea and 103 in the HAT National Control Programme Centre of Forecariah [11]. All enrolled subjects were 104 screened from May 2017 to February 2019 in medical surveys performed by the HAT National 105 Control Programme, according to WHO recommendations and as described previously [12]. A 106 total of 5,417 individuals were screened with the card agglutination test for trypanosomiasis 107 using whole blood samples (CATTwb) (Table 1). For those individuals who tested positive in 108 the CATTwb screening test, 5ml of blood was collected in heparinized tubes and a two-fold 109 plasma dilution series was used to determine the CATT plasma (CATTp) end titre. All 110 individuals with CATTp end titres of 1/4 or higher then underwent a microscopic examination 111 of lymph node aspirate, whenever cervical swollen lymph nodes were present. Blood samples 112 of CATTp-positive individuals were also centrifuged to obtain the buffy coat layer, which was 113 tested for trypanosomes using the mini-anion exchange centrifugation test (mAECT BC) [13]. 114 If trypanosomes were detected using this test, the infected individual underwent a lumbar 115 puncture and their disease stage was determined by searching for trypanosomes using the 116 modified simple centrifugation technique for CSF and by white blood cell (WBC) counts [14].

117 Gambiense HAT patients were classified as being stage 1 (0-5 WBC/µl and absence of 118 trypanosomes in CSF) or stage 2 (>5 WBC/µl and/or presence of trypanosomes in CSF) and 119 were treated accordingly by the National Control Programme. Treatment consisted of Pentamidine for stage 1 patients (intramuscular injection of 4 mg/kg once daily for 7 days in 120 121 adults) or Nifurtimox-Eflornithine Combination Therapy (NECT) for stage 2 patients (oral 122 Nifurtimox at 15 mg/kg per day in three doses for 10 days and intravenous Eflornithine (α -123 difluoromethylornithine or DFMO) at 400 mg/kg per day in two 2h-infusions for 7 days in 124 adults). All parasitologically confirmed cases in this study were diagnosed and treated 125 according to WHO recommendations.

All confirmed cases (CATTp $\geq 1/4$ with parasitological confirmation) and all unconfirmed 126 127 seropositive individuals (CATTp $\geq 1/4$ without parasitological confirmation) were proposed for 128 study enrolment. Seronegative controls were randomly selected, and approximately two age-129 matched seronegative controls for every seropositive case were enrolled from the same village. Among the 40 seronegative controls, the first 29 individuals enrolled in the study in 130 131 2017 were only included in the epidemiological and clinical analysis but were not sampled for 132 biological analyses, whereas the last 11 individuals enrolled in 2019 were subjected to the 133 entire protocol, according to the recommendations from the national ethical committee of 134 the Republic of Guinea. In total, 5/8 and 4/8 unconfirmed seropositive individuals were 135 followed-up at 6 months and 20 months after enrolment, respectively, and 17/18 and 12/18 136 confirmed cases were followed-up at 6 months and 20 months after treatment, respectively 137 (Table 4). Children under 16 years of age and pregnant women were excluded from the study. 138 Each participant was informed about the study's objectives in their own language and 139 provided written informed consent. For participants between 16 to 18 years of age, informed

140 consent was also obtained from their parents. The data of individual study participants were141 randomly anonymized with a 4-digit code at enrolment.

142 Field procedure and sampling

143 At enrolment, each participant underwent an epidemiological interview and a clinical 144 examination, during which dermatological symptoms were assessed by a trained 145 dermatologist (AMS), as well as at each subsequent follow-up at 6 and 20 months after 146 enrolment/treatment. This interview and clinical examination were performed for all 147 confirmed seropositive cases, all unconfirmed seropositive individuals, and for all 148 seronegative controls. The following epidemiological data were collected: age (in years), sex, 149 clinical history of HAT infections in the family since 2010, and occupational risk (occurrence of 150 any regular activities such as farming, hunting, fishing, wood-cutting and/or mining, during 151 which an individual might be more exposed to tsetse bites). The following general clinical data 152 were also collected during the interview: body temperature, presence of swollen cervical lymph nodes, weight loss, asthenia, eating disorders, sexual dysfunctions, repetitive 153 154 headaches, circadian rhythm disruptions and/or any other behavioural changes during the last 155 three months. Dermatological signs of pruritus (skin itch) and dermatitis (skin inflammation) 156 were also investigated and a careful examination of the entire body was performed, in order 157 to detect any symptoms that might be related to skin infections.

Finally, a 2mm blood-free skin punch biopsy was sampled in sterile conditions from the right back shoulder of all confirmed seropositive cases, all unconfirmed seropositive individuals, and for the final 11 seronegative controls. Biopsies were performed under local anaesthesia, and were rapidly dressed. Touch preparations were obtained by gently rolling the biopsy on a clean glass slide. The slides were air-dried, fixed in methyl alcohol, and stained with Giemsa (RAL 555 kit) for microscopic observation in the field. Biopsies were then rapidly fixed in 10%

neutral buffered formalin for immuno-histochemistry and molecular analyses. Plasma aliquots
 from blood samples were also obtained during the screening step for use in serological
 trypanolysis tests, as described below.

167 Immune trypanolysis test

A plasma sample from all confirmed seropositive cases, all unconfirmed seropositive individuals and from the final 11 seronegative controls was used to perform the immune trypanolysis test. This test detects complement-mediated immune responses activated by either the LiTat 1.3, LiTat 1.5 or LiTat 1.6 variable surface antigens specific for *T. b. gambiense*, as previously described [15].

173 Immunohistochemical detection of trypanosomes

174 Skin biopsy samples were fixed in formalin, trimmed and processed into paraffin blocks in the lab. Longitudinal sections of ~2.5µm were then prepared and processed using Dako 175 176 Autostainer Plus (Dako, Denmark). Sections were stained with haematoxylin-eosin (HE) and 177 Giemsa stains. They were also immunolabelled with the T. brucei-specific, anti-ISG65 178 antibody, which targets the Invariant Surface Glycoprotein 65 (rabbit 1/800; gift from M. 179 Carrington, Cambridge, UK) [16], and with the *T. brucei*-specific, anti-Hsp70 antibody, which 180 recognizes the endoplasmic reticulum molecular chaperone heat-shock protein 70 homologue 181 (rabbit 1/2000; gift from J.D. Bangs, Buffalo, USA) [17]. For immunolabelling, the appropriate 182 horseradish peroxidase-coupled secondary antibodies were used, and the staining was 183 revealed with 3,3'-diaminobenzidine and counterstained with Gill's haematoxylin. A noninfected West African skin specimen (Tissue Solutions Ltd., UK) and a T. b. gambiense-infected 184 185 mouse skin specimen were also included with the samples as technical negative and positive 186 controls, respectively. Immunostaining images were acquired using an Axio Observer Z1 187 microscope (Carl Zeiss, Germany) or a Leica 4000B microscope (Leica, Germany), and were

188 analysed using the ImageJ 1.49v software (NIH, USA). In total, all biopsies were analysed in 189 parallel using up to four distinct immuno-histochemical staining. The slides from each biopsy 190 were assessed in a blinded protocol by at least two readers, with results confirmed by up to 191 two more independent trained readers (providing an average of 8 distinct slide reads per 192 subject at enrolment and 4 distinct reads per subject for each follow-up session). Slides from 193 the 11 seronegative controls were randomly mixed with slides from the seropositive cases in 194 order to guarantee blind reading. The positivity of a given skin-section slide was defined by 195 the detection of at least three, clearly distinguishable trypanosomes.

196 DNA extraction

197 Three, 10µm-thick sections were cut from each remaining paraffin- embedded skin specimen, 198 with the blade being changed between samples. A non-infected West African skin specimen 199 (Tissue Solutions Ltd., UK) and a T. b. gambiense-infected mouse skin specimen were also 200 included with the samples as negative and positive technical controls, respectively. DNA was 201 then extracted from the sections using Deparaffinization Solution (Qiagen, Germany) and the 202 QIAamp DNA FFPE Tissue Kit (Qiagen, Germany), following the manufacturer's instructions. 203 For blood samples, DNA extraction was performed on 1ml blood aliquots using the DNeasy 204 Tissue kit (Qiagen, Germany), following the manufacturer's recommendations [18].

205 PCR detection of trypanosome DNA

206 PCR detection of T. brucei s. I. parasites was performed using published primers, which 207 hybridize to a 177bp DNA satellite repeat sequence (10,000 copies per cell) to generate a 208 117bp amplicon as previously described [19]. All PCR results were confirmed using new 5'-209 primers (TBRN3-F 5'-TAAATGGTTCTTATACGAATGA-3' TBRN3-R and 210 TTGCACACATTAAACACTAAAGAACA-3') that externally flank the first primer pair to generate 211 a larger fragment of 168bp. T. b. gambiense-specific PCR directed against the single copy

TgsGP gene was also performed using published primers (308bp amplicon), as previously
described [20], or by using a combination of new (5'-TATGCCGGCTACGGCACCAA-3') and
published (5'-GGGCTCCTGCCTCAATTGCTGCA-3') [21] primers in order to reduce the amplicon
to 97bp.

216 Data analyses

217 General descriptive analyses of anonymized data were performed using Excel 16.16.11 218 (Microsoft, USA). Statistical analyses were performed using XLSTAT Biomed 2019.2.1 219 (Addinsoft, France) and Prism V.8.3.0 (GraphPad, USA) software. For epidemiological, clinical 220 and diagnostic parameters, differences between seronegative controls versus unconfirmed 221 seropositive individuals and confirmed cases were assessed using the following two-sided 222 tests at 5% confidence: Fisher's exact tests for qualitative data (Tables 2 and 3) and/or Mann-Whitney tests for quantitative data (age in Table 2). For the follow-up analyses, differences 223 between results at enrolment versus results at 6 months and 20 months after 224 225 treatment/enrolment were assessed for each group using two-sided Fisher's exact tests at 5% 226 confidence (Table 4).

227 Results

228 Epidemiological and clinical results

229 5,417 individuals were initially screened using the card agglutination test for trypanosomiasis 230 on whole-blood (CATTwb). For CATTwb-positive individuals, a further CATT test was 231 performed on plasma (CATTp) for serological validation. These tests identified 5,377 232 seronegative individuals (CATTwb-negative or CATTp<1/4), of whom 40 were enrolled as 233 seronegative controls, of whom 11 provided skin biopsies (Table 1). Among seropositive 234 individuals (CATTwb-positive and CATTp $\geq 1/4$), 12 were negative for infection based on 235 parasitological examination (prevalence of 0.22%), 8 of whom were enrolled as non-confirmed 236 seropositive individuals (Table 1). 28 cases were found to be seropositive (CATTwb-positive 237 and CATTp $\geq 1/4$) and further confirmed by parasitological observations (prevalence of 0.52%), including 8 stage-1 and 18 stage-2 cases, of whom 4 stage-1 and 14 stage-2 cases were 238 239 enrolled as confirmed gHAT cases (Table 1). In total, 66 seronegative and seropositive 240 (confirmed and non-confirmed) individuals were enrolled in this study and were placed into 241 groups, depending on their screening, validation and confirmation results (Table 1).

242 An epidemiological and clinical assessment was performed on all enrolled subjects, including 243 a dermatological assessment (Table 2). None of the four studied epidemiological parameters 244 (age, sex, occupational risk, and clinical history of gHAT in the family) differed significantly 245 between study groups (Table 2). Clinical symptoms such as asthenia (P<0.0001), fever 246 (P=0.0013) and weight loss (P=0.0046) were statistically (Fisher's exact test) more frequent in 247 confirmed cases (n=18), as compared to seronegative controls (n=40) (Table 2). A particularly 248 marked result (P<0.0001) was the presence of swollen cervical lymph nodes in 94% (17/18) of 249 the confirmed cases and in 75% (6/8) of the unconfirmed seropositive cases, as compared to 250 13% (5/39) of the seronegative controls (Table 2).

251 Among the various observed clinical manifestations of localized dermatitis, we unambiguously 252 identified typical cases of intertrigo (in 4/18 confirmed cases versus 2/40 seronegative 253 controls), pityriasis (in 3/18 versus 2/40), scabies (in 3/18 versus 1/40), dermatophytosis (in 3/18 versus 1/40), molluscum (in 3/18 versus 1/40), and ulceration (in 3/18 versus 1/40). 254 255 Apart from general pruritus and intertrigo, all dermatological signs were observed in upper 256 regions of the body, especially on the thorax and arms. Confirmed cases of trypanosomiasis 257 (83%, 15/18) were significantly more frequently affected by any types of dermatitis than were 258 seronegative controls (18%, 7/40) (P<0.0001 by Fisher's exact test) (Table 2). Oedematous 259 faces were observed in four confirmed cases, and a general pruritus was reported in 64% (9/14) of the stage-2 cases, as compared to 5% (2/40) of the seronegative controls. In total, 260 261 individuals with confirmed cases of gHAT presented with general or localized pruritus significantly more frequently (61%, 11/18) than did seronegative controls (8%, 3/40) 262 263 (P<0.0001 by Fisher's exact test) (Table 2). For unconfirmed seropositive individuals, an 264 intermediate situation was observed; these individuals had a significantly higher rate of 265 dermatitis (63%, including 1/8 with pityriasis, 2/8 with intertrigo and 3/8 with eczema) relative 266 to seronegative controls (18%, 7/40) (P=0.0166 by Fisher's exact test), but lower than that of 267 confirmed cases (83%, 15/18) (Table 2).

268 <u>Biological results</u>

Plasma from all confirmed and unconfirmed seropositive cases, and from the final 11 seronegative controls, was assessed using the trypanolysis test, which detects complementmediated immune responses activated by *T. b. gambiense*-specific antigens. All confirmed cases were positive for the LiTat 1.3 antigen, and 89% (16/18) of these cases were positive for both the LiTat 1.5 and 1.6 antigens (Table 3). These results agree with the serological test results, which indicate that these individuals have an active trypanosome infection, at least in

275 the blood compartment. However, only 25% (2/8) of the unconfirmed seropositive individuals 276 were positive for all antigens; the remainder were negative for all three variants (Table 3). 277 Before a single 2mm skin punch biopsy was sampled from all confirmed and unconfirmed 278 seropositive cases and from 11/40 seronegative controls, the absence of dermatitis lesions at 279 the skin sampling site was verified. Dermal touch preparations were then generated from the 280 biopsy samples, Giemsa-stained and read in the field. Sub-optimal ambient conditions (31±1°C 281 at 75±6% humidity on average) during the preparation of these slides meant that their quality 282 was sub-optimal (S1 Fig.). However, full length trypanosomes were observed on slides from 81% (13/16) of the clinical cases and from 33% (2/6) of the unconfirmed, seropositive 283 284 individuals, with these results blindly confirmed by at least two independent slide readers 285 (Table 3 and S1 Fig.). One of the unconfirmed seropositive individuals who tested positive in 286 this dermal test, also tested positive in the trypanolysis test.

287 The skin biopsy samples were then fixed with formalin and later processed for 288 immunohistochemistry analyses (IHC) in the lab. Skin samples obtained from the seronegative 289 controls (11/11) did not test positive for trypanosomes, neither following staining by Giemsa 290 and haematoxylin-eosin (HE) nor for the T. brucei-specific antibodies used in this study (Table 291 3). By contrast, all unconfirmed seropositive individuals (8/8) and all confirmed cases (18/18) were found to be positive at least following staining by a *T. brucei*-specific anti-ISG65 antibody 292 293 targeting the Invariant Surface Glycoprotein 65 expressed at the surface of the mammalian 294 host stages of *T. brucei s. l.* parasites (Fig. 1, S2 Fig. and Table 3). In addition, all samples from 295 non-confirmed seropositive individuals and confirmed cases were also found to be positive 296 following either unspecific Giemsa staining and/or unspecific HE staining and/or labelling with 297 a *T. brucei*-specific anti-Hsp70 antibody (Fig. 1, S2 Fig. and Table 3).

In positive skin sections, *T. brucei* parasites were evenly distributed in the reticular dermis, and were occasionally associated with oedema. To verify the size of the observed trypanosome cell sections, morphometric measurements were obtained from Giemsa-stained and ISG65-labelled skin-sections (Fig. 1 and S2 Fig.). These measurements show that the mean parasite length was 15.0 ±4.1 μ m (n=293) in Giemsa-stained images and 15.9 ±3.7 μ m (n=109) in ISG65-labelled images.

304 To confirm the identity of these skin-dwelling parasites, *T. brucei*-specific PCR (TBR-PCR) 305 assays were performed on total DNA extracted from fresh blood and from paraffin-embedded 306 skin samples. Both blood and skin DNA samples from the seronegative controls (11/11) were 307 found to be negative for trypanosome DNA by the TBR-PCR assays. By contrast, 100% of blood 308 (18/18) and 78% of skin samples (14/18) from confirmed cases tested positively in the TBR-309 PCR assays. However, parasite DNA was only detected in the skin of unconfirmed seropositive 310 individuals (75%, 6/8) but not in their blood (0/8) (Table 3). The less sensitive T. b. gambiense-311 specific TgsGP-PCR, which amplifies a single-copy gene, was performed on the same DNA 312 samples and was positive for only 67% (12/18) of the blood samples of confirmed cases (Table 313 3). We reasoned that the use of fresh skin biopsies would be more appropriate for TgsGP-PCR. To test this hypothesis, we therefore obtained fresh skin samples, conserved in stabilization 314 315 buffer, from an outgroup of nine additional confirmed cases, who were identified in 2018 316 using the same study protocol and who were living in the same district (S1 Table). These fresh 317 skin samples from 89% (8/9) of these confirmed cases were found to be positive for 318 trypanosome infection by TBR-PCR, while three cases (33%) were also found to be positive by 319 TgsGP-PCR (S1 Table).

320 Follow-up results

321 The same panel of analyses were repeated at 6 and 20 months after study enrolment of the 322 unconfirmed seropositive individuals, and at 6 and 20 months after treatment of the 323 confirmed cases (Table 4). Most of the clinical symptoms associated with the stage-2 cases at 324 enrolment significantly decreased in frequency during the first 6 months after treatment 325 (Table 4). A similar trend was observed for the stage-1 cases, with a statistically significant 326 decrease in the frequency of dermatitis 20 months after treatment (P=0.0286 by Fisher's exact 327 test) (Table 4). The clearance of parasites from the blood and skin of all stage-2 cases who were followed-up at 20 months after treatment was assessed by a statistically significant 328 reduction (Fisher's exact test) in the number of positive results from the following assays: 329 330 CATTwb (from 13/13 at enrolment to 4/9 at 20 months, P=0.0048), CATTp (from 13/13 to 0/9, 331 P<0.0001), parasitological examination of body fluids (from 13/13 to 0/9, P<0.0001), trypanolysis test (from 13/13 to 5/9 LiTat1.3-positive, P=0.0172), TBR-PCR assays on blood 332 333 (from 13/13 to 0/9, P<0.0001) and skin (from 12/13 to 0/9, P<0.0001), and by IHC analyses 334 following labelling with an anti-Hsp70 antibody (from 11/12 to 0/9, P<0.0001) and an anti-335 ISG65 antibody (from 13/13 to 0/9, P<0.0001) (Table 4). Parasitological observations and PCR 336 results became negative within 6 months of treatment in all confirmed cases (17/17) (Table 337 4). Twenty months after treatment, all confirmed cases (12/12) returned a negative result in 338 the trypanolysis test against LiTat 1.6 and in the IHC analyses of skin sections (Table 4). 339 However, at the end of the study, 67% (2/3) of the stage-1 cases and 44% (4/9) of the stage-2 340 cases still had positive results in the CATTwb test, and 100% (3/3) of the stage-1 cases and 341 56% (5/9) of the stage-2 cases, still had positive results in the trypanolysis test against LiTat 342 1.3 (Table 4). In addition, swollen lymph nodes were still detectable in 2 out of 3 stage-1 and 343 in 3 out of 9 stage-2 cases (Table 4). For the 5 unconfirmed seropositive individuals who were

344 monitored after enrolment, no obvious variations were observed in any of their clinical 345 parameters over time (Table 4). Although 2 out of 4 unconfirmed seropositive individuals were 346 found to still be positive for CATTp 20 months after enrolment, their TBR-PCR results on skin 347 DNA and IHC staining results became negative over time. Of the six individuals who were in 348 the unconfirmed seropositive group (n=8), and who tested positive for dermal trypanosomes 349 by both TBR-PCR and IHC analyses at enrolment, three were lost for follow-up before 6 350 months (due to one death, one pregnancy and one resignation). In addition, the unconfirmed 351 seropositive subject, who was still positive after 6 months for the CATTp, the trypanolysis test 352 and the skin biopsy IHC with the anti-ISG65 antibody, refused to participate at the 20 months follow-up. However, during an active surveillance campaign in November 2019 (i.e. after the 353 354 end of this study), this individual was diagnosed as being a stage-1 confirmed case (CATTwb 355 +, CATTp 1/8, mAECT BC +, CSF - and WBC 4) and was treated accordingly.

356 Discussion

Here, we set out to investigate whether *T. b. gambiense* parasites might be found in the skin of confirmed gHAT cases, as well as in unconfirmed seropositive individuals, in regions of active disease transmission. Although this study is somewhat limited to a restricted population and to the detection methods used, 100% of the confirmed cases and unconfirmed seropositive subjects were found to carry extravascular trypanosomes in their skin.

362 Detection of trypanosomes

363 Routine molecular analyses by TBR-PCR confirmed the presence of *T. brucei s. I.* parasites in 364 both the blood and skin of confirmed cases. However, parasite DNA was only detected in the 365 skin of unconfirmed seropositive individuals, which might underlie their infectious status in 366 the extravascular compartment. In contrast, no positive results were found by T. b. 367 *gambiense*-specific TgsGP-PCR on DNA extracted from paraffin-embedded skin samples, likely 368 due to the low sensitivity of this method, which targets a single-copy gene. However, the 369 positivity of some direct TgsGP-PCR assays, performed on fresh skin DNA samples from an 370 outgroup of confirmed cases, suggests that the trypanosomes found in the dermis of the 371 confirmed cases enrolled in the present study are likely to be T. b. gambiense parasites.

372 The trypanolysis test results were also compatible with previous reports [12]. Nevertheless, it 373 is noteworthy that, within the limits of the method used, 6 out of 8 unconfirmed seropositive 374 subjects gave a negative trypanolysis test result, despite the presence of skin-dwelling 375 parasites in these individuals, as confirmed by histological approaches. In 2 of these 376 unconfirmed seropositive subjects who had a positive trypanolysis test result, trypanosomes 377 were also detected in their skin samples by at least 2 distinct histological approaches and by 378 PCR. These observations suggest that unconfirmed seropositive subjects who have negative 379 trypanolysis test results carry trypanosomes in the extravascular compartment. In addition,

although anti-LiTat1.3 antibodies were detected by CATT in the plasma of these unconfirmed seropositive subjects, the trypanolytic activity of these anti-LiTat1.3 antibodies appeared limited as assessed by the negativity of the corresponding trypanolysis tests. The apparent lack of congruence between results of the CATTp and of the trypanolysis test is possibly reflecting a peculiar status of the immune response in some non-confirmed seropositive subjects that remained to be studied more in-depth.

386 Dermatological signs in gHAT

387 Our results indicate that dermatological symptoms might be an important aspect of gHAT's 388 clinical presentation. The few reports that exist on this topic in the literature describe a wide 389 array of skin pathologies associated with sleeping sickness, including pruritus, chancre, rashes 390 and localized oedemas [22, 23]. However, detailed dermatological profiles of HAT cases have 391 mostly been derived from light-skinned travellers with imported HAT, who apparently 392 experience a more rapid disease onset and more skin manifestations than do dark-skinned 393 African patients [23]. Whereas chancres and rashes remain anecdotal, pruritus was the most 394 commonly observed dermatological sign in endemic cases (this condition is present in up to 395 57% of stage-2 cases) [23]. In our study, we observed a higher occurrence of pruritus and 396 dermatitis in unconfirmed seropositive individuals and in confirmed cases, relative to 397 seronegative controls (Table 2). The observed dermatitis profiles included some conditions 398 the aetiologies of which might not be directly related to a trypanosome infection. However, it 399 could be hypothesized that the immune status of the infected host skin is somehow altered 400 by the presence of trypanosomes in a way that promotes the outcome of dermatitis caused 401 by other pathogens and/or increases skin sensitivity. The direct detection of trypanosomes in 402 the human skin is not well documented in the literature [22]. In our immunohistochemical 403 analyses of skin sections, only a limited portion of each parasite cell is visible, because entire

404 trypanosomes do not necessarily lie in the same plan as the 2.5μ m skin sections. For the same 405 reason, the parasite nucleus, kinetoplast and flagellum are rarely all visible in the same given 406 cell section. However, the specificity of the anti-ISG65 and anti-Hsp70 antibodies used in this 407 study enabled the slide readers to unambiguously detect most trypanosomes within the 408 extracellular dermal matrix in a blinded analysis of skin samples. The detection of skin-409 dwelling parasites at enrolment in most of the 2mm skin punch biopsies sampled from 410 seropositive individuals indicates that skin-dwelling parasites might be present over a 411 considerable proportion of the skin surface. In this study, the choice of the sampling site was 412 guided by preliminary observations recorded in the clinical files of previously confirmed cases in the same region; these cases presented with pruritus more frequently in the upper regions 413 of the body. We reasoned that these bouts of itching could have been provoked by dermal 414 415 trypanosomes, hence the choice of the right shoulder as the skin sampling site in this study. 416 However, the precise dynamics of parasite load and distribution in the extravascular dermal 417 compartment over the course of an infection remains unknown. According to historic 418 (reviewed in [7]) and more recent [9] studies in experimental animal models, skin-dwelling 419 parasites could theoretically be detected in almost the entire skin surface, yet with a variable 420 distribution and at variable local densities.

421 <u>A dermal reservoir of trypanosomes in non-confirmed seropositive individuals</u>

One possible explanation for the persistence of disease foci in certain regions is the presence of animal reservoirs [2]. Another possibility, as increasing evidence suggests, is that traditionally used diagnostic approaches do not detect some *T. b. gambiense* infections among seropositive cases [2]. Indeed, bloodstream parasite numbers in *T. b. gambiense* infections can periodically fluctuate to less than 100 trypanosomes/ml, falling below the detection limit of the most sensitive methods currently in use [24]. Another study estimated that 20-30% of

428 gHAT cases are missed in active case detection by standard parasitological techniques and are 429 left untreated [25]. These infected individuals might ultimately progress to clinical disease or 430 remain almost asymptomatic until undergoing a possible self-cure [2]. Here, for the first time, 431 we provide parasitological evidence for the presence of trypanosomes in eight unconfirmed 432 seropositive subjects. The presence of trypanosomes in the skin of these individuals suggests 433 that the human reservoir of gHAT might be greater than initially thought. In this study, the 434 negative test and assay results obtained on samples from the five unconfirmed seropositive 435 subjects who were followed-up at 20 months suggest that these individuals might have been 436 enrolled during a transient/ending/self-curing infection. In this context, data on the infectious 437 status of the 3 remaining unconfirmed seropositive subjects who were found to have dermal 438 trypanosomes at enrolment, but who were lost from follow-up, would have been informative. 439 However, there remains the case of the unconfirmed seropositive individual, who remained positive for dermal parasites 6 months after enrolment, and who was diagnosed as a 440 441 confirmed stage-1 case in an active screening campaign 31 months after enrolment, after this 442 study had ended. This individual's diagnosis suggests that dermal parasites could play a 443 significant role during the early stage of the disease.

444 <u>Transmission and epidemiological contribution of dermal trypanosomes</u>

Mathematical modelling recently predicted that, in the absence of any animal reservoirs, these unconfirmed seropositive individuals could contribute to disease transmission by maintaining an overlooked reservoir of skin-dwelling parasites [26]. Tsetse feed by lacerating the skin of their host rather than by inserting a proboscis directly into the vasculature. After causing significant local damage at the bite site, the insects ingest the resultant pool of capillary blood and lymph mixed with the surrounding dermal material. Bearing in mind this feeding mechanism and the observation that latent cases host dermal trypanosomes, the skin

452 of such individuals could provide a population of infective parasites that are readily accessible 453 to the tsetse fly. Indeed, this mode of transmission has been demonstrated in experimental 454 animal models, in which skin-dwelling trypanosomes were efficiently transmitted to the tsetse vector, even in the absence of detectable parasitaemia [8, 9, 27]. However, the presence of 455 456 the parasite forms (called stumpy trypanosome stages) that are assumed to be most adapted 457 for development in tsetse flies were not investigated here. This is an important question for 458 future studies to address, in order to estimate the actual infectivity potential of human skin-459 dwelling parasites. Our reported observations should also be confirmed in a larger number of 460 unconfirmed seropositive individuals and seronegative controls, and the study scaled-up to 461 include other endemic transmission foci in Africa, in order to confidently determine the actual 462 prevalence of dermal trypanosomes.

463 <u>Conclusion</u>

Our results also raise questions about the strategies used to diagnose this disease, which 464 currently focus on detecting parasites in the blood and lymph. If the human skin is indeed a 465 466 disease reservoir, it could represent a novel target for diagnostics, and it could: (i) allow more 467 carriers to be treated; (ii) help to determine a more accurate estimate of the true prevalence 468 of the disease; and (iii) help to identify as yet undetected reservoirs in both human and animal 469 populations. The current WHO recommendation, based on risk-benefit analyses, is to not treat 470 unconfirmed seropositive individuals without knowing if they have an active infection [1]. 471 Importantly, we observed that the routinely administered trypanocide treatments 472 (Pentamidine for stage-1 and NECT for stage-2 cases, according to the previous WHO 473 recommendations) efficiently targeted both bloodstream and dermal trypanosomes in all the patients followed-up, as shown by the negative results of all the tests used in this study after 474 475 20 months. With the promise of new cheaper, less toxic and easier to administer drugs on the

476	horizon, the policy of treating unconfirmed seropositive individuals could possibly be
477	reconsidered. Indeed, the drug Acoziborole, which requires a single oral administration, could
478	hopefully be the next revolutionary treatment against gHAT. As gHAT approaches its
479	elimination targets, we propose from our findings that current algorithms, which are used to
480	identify and manage disease cases, could be adapted to include the detection of skin-dwelling
481	parasites, which likely represent a previously unaccounted for anatomical reservoir.
482	

484 Acknowledgements

We thank M. Carrington (Cambridge, UK) and J.D. Bangs (Buffalo, USA) for providing antibodies. We are grateful to Y. Madec (Paris, France) for his help in statistical analysis. We warmly thank the team of the Programme National de Lutte contre la Trypanosomiase Humaine Africaine of Conakry, as well as all our collaborators of the Forecariah District Health Department. We thank Dominique N'Diaye (Paris, France) for his critical reading and Jane Alfred (Catalyst Editorial, UK) for her editorial work on the manuscript.

491 Financial disclosure

This work was supported by the Wellcome Trust (209511/Z/17/Z), the Institut de Recherche
pour le Développement, the Institut Pasteur, the French Government Investissement d'Avenir
programme - Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"
(ANR-10-LABX-62-IBEID) and the French National Agency for Scientific Research (projects
ANR-14-CE14-0019-01 EnTrypa and ANR-18-CE15-0012 TrypaDerm). None of these funding
sources has a direct scientific or editorial role in the present study.

498 Author contributions

MarC, AMS and NRKS conduced the clinical study in the field and commented on the manuscript. HI, IS, CT, CC, ACo, ACr, OC, ECA and JMB performed sample analyses and commented on the manuscript. MamC and VJ held logistical aspects, analysed part of the data and commented on the manuscript. AML*, BB* and BR* designed the study, organised logistical aspects, analysed the data and wrote the manuscript as co-last authors.

504 Competing interest

505 All authors declare no financial relationships with any organisations that might have an 506 interest in the submitted work in the previous three years, no other relationships nor activities

- 507 that could appear to have influenced the submitted work, and no other relationships or
- 508 activities that could appear to have influenced the submitted work.

509 Data and material availability

- 510 Upon request, the original protocol and associated forms, as well as an anonymised dataset,
- 511 could be obtained from the corresponding author rotureau@pasteur.fr.

512 Transparency statement

- 513 The lead author affirms that the manuscript is an honest, accurate and transparent account
- of the study being reported, that no important aspect of the study has been omitted, and that
- 515 any discrepancies from the study as originally planned have been explained.

516 References

Buscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet.
 2017. doi: 10.1016/S0140-6736(17)31510-6. PubMed PMID: 28673422.

Informal Expert Group on *gambiense* HAT, Buscher P, Bart JM, Boelaert M, Bucheton
 B, Cecchi G, et al. Do Cryptic Reservoirs Threaten *gambiense*-Sleeping Sickness Elimination?
 Trends Parasitol. 2018;34(3):197-207. Epub 2018/02/06. doi: 10.1016/j.pt.2017.11.008.
 PubMed PMID: 29396200; PubMed Central PMCID: PMCPMC5840517.

523 3. Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the
524 elimination of human African trypanosomiasis: Update to 2016. PLoS Negl Trop Dis.
525 2018;12(12):e0006890. Epub 2018/12/07. doi: 10.1371/journal.pntd.0006890. PubMed
526 PMID: 30521525.

Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al. New WHO
 guidelines for treatment of *gambiense* human African trypanosomiasis including fexinidazole:
 substantial changes for clinical practice. Lancet Infect Dis. 2020;20(2):e38-e46. Epub
 2019/12/28. doi: 10.1016/S1473-3099(19)30612-7. PubMed PMID: 31879061.

5. Berthier D, Breniere SF, Bras-Goncalves R, Lemesre JL, Jamonneau V, Solano P, et al.
 Tolerance to Trypanosomatids: A Threat, or a Key for Disease Elimination? Trends Parasitol.
 2016;32(2):157-68. doi: 10.1016/j.pt.2015.11.001. PubMed PMID: 26643519.

De Niz M, Meehan GR, Brancucci NMB, Marti M, Rotureau B, Figueiredo LM, et al.
 Intravital imaging of host-parasite interactions in skin and adipose tissues. Cell Microbiol.
 2019;21(5):e13023. Epub 2019/03/03. doi: 10.1111/cmi.13023. PubMed PMID: 30825872;
 PubMed Central PMCID: PMCPMC6590052.

538 7. Goodwin LG. The pathology of African trypanosomiasis. Trans R Soc Trop Med Hyg.
539 1970;64(6):797-817. Epub 1970/01/01. PubMed PMID: 5495630.

Caljon G, Van Reet N, De Trez C, Vermeersch M, Perez-Morga D, Van Den Abbeele J.
 The Dermis as a Delivery Site of *Trypanosoma brucei* for Tsetse Flies. PLoS Pathog.
 2016;12(7):e1005744. doi: 10.1371/journal.ppat.1005744. PubMed PMID: 27441553;
 PubMed Central PMCID: PMCPMC4956260.

Capewell P, Cren-Travaille C, Marchesi F, Johnston P, Clucas C, Benson RA, et al. The
 skin is a significant but overlooked anatomical reservoir for vector-borne African
 trypanosomes. eLife. 2016;5. doi: 10.7554/eLife.17716. PubMed PMID: 27653219; PubMed
 Central PMCID: PMCPMC5065312.

Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco F, et
al. *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the Adipose Tissue in
Mice. Cell Host Microbe. 2016. doi: 10.1016/j.chom.2016.05.002. PubMed PMID: 27237364.

11. Courtin F, Jamonneau V, Camara M, Camara O, Coulibaly B, Diarra A, et al. A
geographical approach to identify sleeping sickness risk factors in a mangrove ecosystem. Trop
Med Int Health. 2010;15(8):881-9. doi: 10.1111/j.1365-3156.2010.02559.x. PubMed PMID:
20545924.

Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, Leno M, et al. Diversity of
response to *Trypanosoma brucei gambiense* infections in the Forecariah mangrove focus
(Guinea): perspectives for a better control of sleeping sickness. Microbes Infect.
2011;13(11):943-52. doi: 10.1016/j.micinf.2011.05.007. PubMed PMID: 21658462.

13. Camara M, Camara O, Ilboudo H, Sakande H, Kabore J, N'Dri L, et al. Sleeping sickness
diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange
centrifugation test. Trop Med Int Health. 2010;15(7):796-9. doi: 10.1111/j.13653156.2010.02546.x. PubMed PMID: 20497407.

Miezan TW, Meda HA, Doua F, Dje NN, Lejon V, Buscher P. Single centrifugation of
cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of
trypanosomes. Trans R Soc Trop Med Hyg. 2000;94(3):293. Epub 2000/09/07. PubMed PMID:
10975002.

567 15. Van Meirvenne N, Magnus E, Buscher P. Evaluation of variant specific trypanolysis tests
568 for serodiagnosis of human infections with *Trypanosoma brucei gambiense*. Acta Trop.
569 1995;60(3):189-99. Epub 1995/12/01. PubMed PMID: 8907397.

570 16. Ziegelbauer K, Overath P. Organization of two invariant surface glycoproteins in the
571 surface coat of *Trypanosoma brucei*. Infect Immun. 1993;61(11):4540-5. Epub 1993/11/01.
572 PubMed PMID: 8406850; PubMed Central PMCID: PMCPMC281202.

573 17. McDowell MA, Ransom DM, Bangs JD. Glycosylphosphatidylinositol-dependent
574 secretory transport in *Trypanosoma brucei*. Biochem J. 1998;335 (Pt 3):681-9. Epub
575 1998/10/31. PubMed PMID: 9794811; PubMed Central PMCID: PMCPMC1219832.

576 Koffi M, Solano P, Denizot M, Courtin D, Garcia A, Lejon V, et al. Aparasitemic 18. 577 serological suspects in Trypanosoma brucei gambiense human African trypanosomiasis: a 578 potential human reservoir of parasites? Acta Trop. 2006;98(2):183-8. doi: 579 10.1016/j.actatropica.2006.04.001. PubMed PMID: 16723098.

580 Cunningham LJ, Lingley JK, Haines LR, Ndung'u JM, Torr SJ, Adams ER. Illuminating the 19. 581 Prevalence of *Trypanosoma brucei s.l.* in *Glossina* Using LAMP as a Tool for Xenomonitoring. 582 PLoS 2016;10(2):e0004441. 2016/02/20. Negl Trop Dis. Epub doi: 583 10.1371/journal.pntd.0004441. PubMed PMID: 26890882; PubMed Central PMCID: 584 PMCPMC4758712.

585 20. Radwanska M, Claes F, Magez S, Magnus E, Perez-Morga D, Pays E, et al. Novel primer

586 sequences for polymerase chain reaction-based detection of *Trypanosoma brucei gambiense*.

587 Am J Trop Med Hyg. 2002;67(3):289-95. Epub 2002/11/01. PubMed PMID: 12408669.

Morrison LJ, Tait A, McCormack G, Sweeney L, Black A, Truc P, et al. *Trypanosoma brucei gambiense* Type 1 populations from human patients are clonal and display geographical
genetic differentiation. Infect Genet Evol. 2008;8(6):847-54. Epub 2008/09/16. doi:
10.1016/j.meegid.2008.08.005. PubMed PMID: 18790085.

592 22. McGovern TW, Williams W, Fitzpatrick JE, Cetron MS, Hepburn BC, Gentry RH.

593 Cutaneous manifestations of African trypanosomiasis. Arch Dermatol. 1995;131(10):1178-82.

594 PubMed PMID: 7574836.

Blum JA, Neumayr AL, Hatz CF. Human African trypanosomiasis in endemic populations
and travellers. Eur J Clin Microbiol Infect Dis. 2012;31(6):905-13. Epub 2011/09/09. doi:
10.1007/s10096-011-1403-y. PubMed PMID: 21901632.

598 24. Buscher P, Deborggraeve S. How can molecular diagnostics contribute to the
599 elimination of human African trypanosomiasis? Expert Rev Mol Diagn. 2015;15(5):607-15. doi:
600 10.1586/14737159.2015.1027195. PubMed PMID: 25786994.

Robays J, Bilengue MM, Van der Stuyft P, Boelaert M. The effectiveness of active
population screening and treatment for sleeping sickness control in the Democratic Republic
of Congo. Trop Med Int Health. 2004;9(5):542-50. doi: 10.1111/j.1365-3156.2004.01240.x.
PubMed PMID: 15117297.

605 26. Capewell P, Atkins K, Weir W, Jamonneau V, Camara M, Clucas C, et al. Resolving the 606 apparent transmission paradox of African sleeping sickness. PLoS Biol. 2019;17(1):e3000105.

607 Epub 2019/01/12. doi: 10.1371/journal.pbio.3000105. PubMed PMID: 30633739.

- 608 27. Wombou Toukam CM, Solano P, Bengaly Z, Jamonneau V, Bucheton B. Experimental
- 609 evaluation of xenodiagnosis to detect trypanosomes at low parasitaemia levels in infected
- 610 hosts. Parasite. 2011;18(4):295-302. PubMed PMID: 22091459; PubMed Central PMCID:
- 611 PMCPMC3677595.
- 612

613 Figures

Fig. 1. Extravascular trypanosomes in the dermal matrix of human skin biopsies.

- For each enrolled study subject, paraffin-embedded skin biopsy sections were stained either with (A) a specific anti-ISG65 antibody (brown) or (B) with Giemsa (purple) and screened at a 100x magnification. Representative trypanosome sections from confirmed stage-1 (subject 1044) and stage-2 cases (subjects 1035, 1036, 1037, 1039 and 1042), as well as from unconfirmed seropositive individuals (subjects 1046, 1065 and 1066) are shown. The scale bars represent 10µm. More images of extravascular *T. brucei* parasites in human skin biopsies
- 621 are available in S2 Fig.



623 Supporting information legends

S1 Fig. Giemsa-stained skin biopsy touch-preparations showing trypanosomes among extracellular dermal matrix elements. For most of the enrolled seropositive subjects, bloodfree skin biopsy touch-preps were directly stained with Giemsa in the field and scrutinized at a 100x magnification. Scale bars represent 10μm and white arrows indicate dermal trypanosomes.

629 S2 Fig. Pictures of skin biopsy sections with different immuno-histological staining showing

630 extravascular *T. brucei* parasites in the dermal matrix of both unconfirmed seropositive

631 individuals and confirmed cases. For each enrolled subject identified by a 4-digit code,

632 paraffin-embedded skin biopsy sections were either counterstained with Giemsa, HE, an anti-

633 ISG65 antibody or an anti-Hsp70 antibody and scrutinized at a 100x magnification. Scale bars

634 represent 10μm and white arrows indicate dermal trypanosome sections.

635 S1 Table. Detailed serological and molecular analysis results from blood and skin samples of

additional confirmed cases. CATTwb / CATTp: card agglutination test for trypanosomiasis on
whole blood / plasma; mAECT BC: mini anion-exchange column technic on buffy coat; PCR:
single round polymerase chain reaction; TgsGP: *Trypanosoma brucei gambiense* surface
glycoprotein; +: positive result; -: negative result.

641 Tables

- **Table 1. Diagnostic process, number of subjects and results.**
- 643 CATTwb / CATTp: card agglutination test for trypanosomiasis on whole blood / plasma; mAECT
- BC / LN aspirate: mini anion-exchange column technique on buffy coat / lymph node aspirate;
- 645 WBC: white blood cells; CSF: cerebrospinal fluid; ND: not determined. *Highest plasma
- 646 dilution with a positive result.

			Diagnostic pro	ocess			No. subjects	
Groups	I	1- Serological screening	2- Serological validation	3- Parasitological confirmation	4- Staging	Common	D S S S S S S S S S S S S S S S S S S S	Followed
	l	CATTwb / RDT	CATTp*	mAECT BC/LN aspirate observation	Parasites in No. WBC CSF in CSF	Dateellen	Further	гопомеа-пр
Seron egotive		·	ND	Ę	Ę	775 S	UV	
DUI UII CEAUVC		+	< 1/4		<u>an</u>		D t	
Seropositive		+	≧ 1/4		ND	12	8	5
	Stage 1				no 0-5	8	4	4
Confirmed	Stage 2	+	≧ 1/4	+	yes >5	18	14	13
	ND				ND	2	0	0
	All					28	18	17
Total						5 417	99	22

Table 2. Epidemiological and clinical characteristics of case subjects.

- 650 For each group and each parameter, total values correspond to the numbers of subjects for
- which a value was available (n/total). p values were obtained by comparing one by one the
- 652 parameters of each group of seropositive subjects (unconfirmed and all confirmed) to those
- of seronegative controls using two-sided Fisher's exact tests or * two-sided Mann-Whitney
- 654 tests at 5% confidence. LN: lymph nodes.

				ġ				
				Groul (n=66	so (e			
						Confirme	p	
Doutoutout		Seronegative	Seroposit	ive		(n=18)		
rarameters		(n=40)	(n=8)		Stage 1 (n=4)	Stage 2 (n=14)	All (n=18)	
		n/total (%) or mean (SD)	n/total (%) or mean (SD)	p values	n/total (%) or mean (SD)	n/total (%) or mean (SD)	n/total (%) or mean (SD)	o values
Epidemiological	Age (n=66)	37.9 (14)	36.6 (18)	0.7647*	31.0 (17)	35.6 (15)	34.6 (15)	0.3502*
	Male sex (n=66)	22/40 (55%)	3/8 (38%)	0.4538	2/4 (50%)	5/14 (36%)	7/18 (39%)	0.3950
	HAT case(s) in the family since $2010 (n=65)$	11/40 (28%)	2/7 (29%)	>0.9999	2/4 (50%)	5/14 (36%)	7/18 (39%)	0.5404
	Occupational risk (n=66)	17/40 (43%)	4/8 (50%)	0.7155	2/4 (50%)	5/14 (36%)	7/18 (39%)	>0.9999
Clinical	Swollen LN (n=65)	5/39 (13%)	6/8 (75%)	0.0010	4/4 (100%)	13/14 (93%)	17/18 (94%)	<0.0001
	Any dermatological symptoms (n=66)	8/40 (20%)	5/8 (63%)	0.0252	4/4 (100%)	13/14 (93%)	17/18 (94%)	<0.0001
	Dermatitis (n=66)	7/40 (18%)	5/8 (63%)	0.0166	4/4 (100%)	11/14 (79%)	15/18 (83%)	<0.0001
	Pruritus (n=66)	3/40 (8%)	2/8 (25%)	0.1887	0/4 (0%)	11/14 (79%)	11/18 (61%)	<0.0001
	Asthenia (n=65)	17/39 (44%)	4/8 (50%)	>0.9999	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	Fever (n=63)	6/38 (16%)	1/7 (14%)	>0.9999	2/4 (50%)	9/14 (64%)	11/18 (61%)	0.0013
	Weight loss (n=61)	6/39 (15%)	3/8 (38%)	0.1672	2/4 (50%)	6/10 (60%)	8/14 (57%)	0.0046
	Eating disorders (n=66)	4/40 (10%)	1/8 (13%)	>0.9999	0/4 (0%)	7/14 (50%)	7/18 (39%)	0.0250
	Headache (n=65)	23/39 (59%)	6/8 (75%)	0.6918	3/4 (75%)	13/14 (93%)	16/18 (89%)	0.0322
	Circadian rhythm disruptions (n=66)	3/40 (8%)	1/8 (13%)	0.5303	0/4 (0%)	5/14 (36%)	5/18 (28%)	0.0925
	Sexual dysfunctions (n=65)	4/39 (10%)	1/8 (13%)	>0.9999	0/4 (0%)	5/14 (36%)	5/18 (28%)	0.1236
	Behaviour changes (n=63)	4/39 (10%)	0/7 (0%)	>0.9999	0/4 (0%)	3/13 (23%)	3/17 (18%)	0.6624

Table 3. Serological, molecular and histological analysis results from blood and skin samples.

- For each group and each parameter, total values correspond to the numbers of subjects for which a value was available (n/total). p values were obtained by comparing one by one the parameters of each group of seropositive subjects (unconfirmed and all confirmed) to those of seronegative controls using two-sided Fisher's exact tests at 5% confidence. VAT: variable antigen type; PCR: polymerase chain reaction; TgsGP: *Trypanosoma brucei gambiense* surface
- 663 glycoprotein; HE: haematoxylin-eosin; IHC: immuno-histochemistry; Hsp70: heat shock
- 664 protein 70; ISG65: invariant surface glycoprotein 65; ND: not determined.

				Gro	ups (n=37)			
		Seronegative (n=11)	Seroposit (n=8)	ive		Confirmed (n=18)	в	
rarameters					Stage 1 (n=4)	Stage 2 (n=14)	All (n=18)	
		n/total (%)	n/total (%)	p values	n/total (%)	n/total (%)	n/total (%)	p values
Trypanolysis	LiTat 1.3 positive (n=36)	0/10 (0%)	2/8 (25%)	0.1830	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	LiTat 1.5 positive (n=36)	0/10 (0%)	2/8 (25%)	0.1830	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	LiTat 1.6 positive (n=36)	0/10 (0%)	2/8 (25%)	0.1830	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	Positive for all VATs (n=36)	0/10 (0%)	2/8 (25%)	0.1830	4/4 (100%)	12/14 (86%)	16/18 (89%)	<0.0001
	Negative for all VATs (n=36)	10/10 (100%)	6/8 (75%)	0.1830	0/4 (0%)	0/14 (0%)	0/18 (0%)	<0.0001
PCR on blood	TBR positive $(n=37)$	0/11 (0%)	0/8 (0%)	>0.9999	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	TgsGP positive (n=37)	0/11 (0%)	0/8 (0%)	>0.9999	2/4 (50%)	10/14 (71%)	12/18 (67%)	0.0004
	Negative for all PCRs on blood $(n=37)$	11/11 (100%)	8/8 (100%)	>0.9999	0/4 (0%)	0/14 (0%)	0/18 (0%)	<0.0001
PCR on skin	TBR positive $(n=37)$	0/11 (0%)	6/8 (75%)	0.0010	1/4 (25%)	13/14 (93%)	14/18 (78%)	<0.0001
	TgsGP positive (n=37)	0/11 (0%)	0/8 (0%)	>0.9999	0/4 (0%)	0/14 (0%)	0/18 (0%)	>0.9999
	Negative for all PCRs on skin (n=37)	11/11 (100%)	2/8 (25%)	0.0010	3/4 (75%)	1/14 (7%)	4/18 (22%)	<0.0001
Histology	Dermal touchpreps (n=22, 3 reads)	ΟN	2/6 (33%)		1/3 (33%)	12/13 (92%)	13/16 (81%)	
	HE section $(n=36, 1 \text{ read})$	0/11 (0%)	6/8 (75%)	0.0010	4/4 (100%)	8/13 (62%)	12/17 (71%)	0.0003
	Giemsa section (n=37, 2 reads)	0/11 (0%)	4/8 (50%)	0.0181	0/4 (0%)	14/14 (100%)	14/18 (78%)	<0.0001
	IHC Hsp70 $(n=31, 1 \text{ read})$	0/11 (0%)	1/4 (25%)	0.2667	1/4 (25%)	11/12 (92%)	12/16 (75%)	0.0002
	IHC ISG65 $(n=37, 3 \text{ reads})$	0/11 (0%)	8/8 (100%)	<0.0001	4/4 (100%)	14/14 (100%)	18/18 (100%)	<0.0001
	Negative for all reads $(n=37)$	11/11 (100%)	0/8 (0%)	<0.0001	0/4 (0%)	0/17 (0%)	0/18 (0%)	<0.0001

Table 4. Clinical, serological, molecular and histological follow-up analyses at 6 and 20

668 months after enrolment.

- Total values correspond to the numbers of subjects for which a value was available (n/total).
- 670 For each group of subjects, p values were obtained by comparing one by one the parameters
- 671 recorded at 6 months and 20 months after treatment/enrolment to those obtained at
- 672 enrolment, using two- sided Fisher's exact tests at 5% confidence. LN: lymph nodes; CATT:
- 673 card agglutination test for trypanosomiasis; VAT: variable antigen type; PCR: TBR polymerase
- 674 chain reaction; Hsp70: heat shock protein 70; ISG65: invariant surface glycoprotein 65; ND:
- 675 not determined.

			Comon o difino				Confir	med		
aramatare			avnieodorac			Stage 1			Stage 2	
		Enrollment	6 months	20 months	Enrollment	6 months	20 months	Enrollment	6 months	20 months
		n/total (%)	n/total (%) <i>p values</i>	n/total (%) <i>p values</i>	n/total (%)	n/total (%) <i>p values</i>	n/total (%) <i>p values</i>	n/total (%)	n/total (%) p values	n/total (%) <i>p values</i>
Clinics	Asthenia	3/5 (60%)	1/5 (20%) 0.5238	2/4 (50%) > 0.9999	4/4 (100%)	0/4 (0%) 0.0286	2/3 (67%) 0.4286	13/13 (100%)	3/13 (23%) 0.0001	3/9 (33%) 0.0011
	Swollen LN	4/5 (80%)	1/4 (25%) 0.2063	3/4 (75%) >0.9999	4/4 (100%)	2/3 (67%) 0.4286	2/3 (67%) 0.4286	12/13 (92%)	2/11 (18%) 0.0005	3/9 (33%) 0.0066
	Any dermatological symptoms	4/5 (80%)	1/5 (20%) 0.2063	1/4 (25%) 0.2063	4/4 (100%)	1/4 (25%) 0.1429	0/3 (0%) 0.0286	12/13 (92%)	5/13 (38%) 0.0112	3/9 (33%) 0.0066
	Fever	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	2/4 (50%)	0/4 (0%) 0.4286	0/3 (0%) 0.4286	9/13 (69%)	0/13 (0%) 0.0005	1/9 (11%) 0.0115
	Headache	5/5 (100%)	2/5 (40%) 0.1667	3/4 (75%) 0.4444	3/4 (75%)	0/4 (0%) 0.1429	0/3 (0%) 0.1429	12/13 (92%)	2/13 (15%) 0.0002	4/9 (44%) 0.0231
	Pruritus	1/5 (20%)	0/5 (0%) > 0.9999	1/4 (25%) > 0.9999	0/4 (0%)	0/4 (0%) > 0.9999	0/3 (0%) >0.9999	10/13 (77%)	3/13 (23%) 0.0169	2/9 (22%) 0.0274
	Weight loss	2/5 (40%)	2/5 (40%) >0.9999	0/4 (0%) 0.4444	2/4 (50%)	1/4 (25%) >0.9999	0/3 (0%) 0.4286	5/9 (56%)	0/13 (0%) 0.0048	0/9 (0%) 0.0294
	Dermatitis	4/5 (80%)	1/5 (20%) 0.2063	1/4 (25%) 0.2063	4/4 (100%)	1/4 (25%) 0.1429	0/3 (0%) 0.0286	10/13 (77%)	5/13 (38%) 0.1107	3/9 (33%) 0.0789
	Eating disorders	1/5 (20%)	1/5 (20%) >0.9999	1/4 (25%) > 0.9999	0/4 (0%)	0/4 (0%) > 0.9999	0/3 (0%) >0.9999	6/13 (46%)	0/13 (0%) 0.0149	1/9 (11%) 0.1649
	Sex ual dysfunctions	1/5 (20%)	3/5 (60%) 0.5238	0/4 (0%) > 0.9999	0/4 (0%)	0/4 (0%) > 0.9999	0/3 (0%) >0.9999	5/13 (38%)	5/13 (38%) >0.9999	1/9 (11%) 0.3330
	Circadian rhythm disruptions	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	0/4 (0%)	0/4 (0%) >0.9999	0/3 (0%) >0.9999	4/13 (31%)	1/13 (8%) 0.3217	1/9 (11%) 0.3602
	Behaviour changes	0/4 (0%)	1/5 (20%) > 0.9999	0/4 (0%) > 0.9999	0/4 (0%)	0/4 (0%) > 0.9999	0/3 (0%) > 0.9999	2/12 (17%)	0/13 (0%) 0.2200	0/9 (0%) 0.4857
Diagnosis	CATTwb	5/5 (100%)	4/5 (80%) > 0.9999	3/4 (75%) 0.4444	4/4 (100%)	4/4 (100%) >0.9999	2/3 (67%) 0.4286	13/13 (100%)	10/13 (77%) 0.2200	4/9 (44%) 0.0048
	CATTp	5/5 (100%)	1/5 (20%) 0.0476	2/4 (50%) 0.1667	4/4 (100%)	0/4 (0%) 0.0286	1/3 (33%) 0.1429	13/13 (100%)	3/13 (23%) 0.0001	0/9 (0%) <0.0001
	Parasitology	0/5 (0%)	0/5 (0%) > 0.9999	0/4 (0%) > 0.9999	4/4 (100%)	0/4 (0%) 0.0286	0/3 (0%) 0.0286	13/13 (100%)	0/13 (0%) <0.0001	0/9 (0%) <0.0001
Frypanolysis	LiTat 1.3 positive	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	4/4 (100%)	4/4 (100%) >0.9999	3/3 (100%) > 0.9999	13/13 (100%)	10/11 (91%) 0.2200	5/9 (56%) 0.0172
	LiTat 1.5 positive	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	4/4 (100%)	4/4 (100%) >0.9999	2/3 (67%) 0.4286	11/13 (85%)	8/11 (73%) 0.6299	5/9 (56%) 0.1778
	LiTat 1.6 positive	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	4/4 (100%)	4/4 (100%) >0.9999	0/3 (0%) 0.0286	11/13 (85%)	6/11 (54%) 0.1819	0/9 (0%) 0.0002
	Positive for all VATs	1/5 (20%)	1/5 (20%) >0.9999	0/4 (0%) > 0.9999	4/4 (100%)	4/4 (100%) >0.9999	0/3 (0%) 0.0286	11/13 (85%)	6/11 (54%) 0.1819	0/9 (0%) 0.0002
	Negative for all VATs	4/5 (80%)	4/5 (80%) > 0.9999	4/4 (100%) > 0.9999	0/4 (0%)	0/4 (0%) > 0.9999	0/3 (0%) >0.9999	0/13 (0%)	1/11 (9%) 0.4583	3/9 (33%) 0.0545
TBR PCR	Blood	0/2 (0%)	0/5 (0%) > 0.9999	0/4 (0%) > 0.9999	4/4 (100%)	0/4 (0%) 0.0286	0/3 (0%) 0.0286	13/13 (100%)	0/13 (0%) <0.0001	0/9 (0%) < 0.0001
	Skin	3/5 (60%)	0/5 (0%) 0.1667	0/4 (0%) 0.1667	1/4 (25%)	0/4 (0%) > 0.9999	0/3 (0%) > 0.9999	12/13 (92%)	0/13 (0%) <0.0001	0/9 (0%) <0.0001
Histology	Dermal touchpreps	1/3 (33%)	0/2 (0%) > 0.9999	ND	1/3 (33%)	1/4 (25%) >0.9999	ND	11/12 (92%)	2/13 (15%) 0.0002	ND
	IHC Hsp 70	1/4 (25%)	ŊŊ	0/4 (0%) > 0.9999	1/4 (25%)	ND	0/3 (0%) >0.9999	11/12 (92%)	QN	0/9 (0%) < 0.0001
	IHC ISG65	5/5 (100%)	1/5 (20%) 0.0476	0/4 (0%) 0.0079	4/4 (100%)	0/4 (0%) 0.0286	0/3 (0%) 0.0286	13/13 (100%)	5/13 (38%) 0.0016	0/9 (0%) <0.0001
	Negative for all reads	0/5 (0%)	2/5 (40%) 0.4444	4/4 (100%) 0.0079	0/4 (0%)	2/4 (50%) 0.4286	2/3 (67%) 0.1429	0/13 (0%)	1/13 (8%) >0.9999	9/9 (100%) <0.0001